Peter V Allen
Mr Allen was appointed as Non-Executive Chairman of the Group in January 2014. He is currently the Non-Executive Chairman of AIM listed Abcam plc. He is also a Non- Executive Director of Istesso Limted, and a qualified Chartered Accountant.
Mr Allen has extensive experience in the healthcare industry, having held key senior positions in a number of companies and playing a significant role in their development. This includes 12 years at Celltech Group plc (1992-2004) as CFO and Deputy CEO, six years as Chairman (2007-2013) of ProStrakan Group plc (Interim CEO 2010-11), three years as Chairman of Proximagen Neurosciences plc (2009-12), five years as Non-Executive Chairman of Diurnal plc (2015-2020), nine years as Non-Executive Chairman of Clinigen plc (2012-2021) and 11 years as a Non-Executive Director and Non-Executive Chairman of Oxford Nanopore Technologies plc (2011-2022).
Chief Executive Officer
Chris Meredith joined AMS as Group Commercial Director in July 2005 following a successful 18-year career in international healthcare sales, marketing and business development. His experience covered business-tobusiness contract manufacturing, product development and clinical research, as well as branded product sales all within the medical device, pharmaceutical or consumer healthcare markets. Chris has previously held senior positions at Smiths Industries, Cardinal Health, Banner Pharmacaps, and Aster Cephac. He was appointed Managing Director of Advanced Woundcare in February 2008, became Chief Operating Officer in January 2010 and was appointed as Chief Executive Officer in January 2011.
Chris Meredith was appointed Chairman of Arterius, a UK based pre-commercial, none competitive medical device company, in January 2022. He left his role as a Non-Executive of Creavo Medical Technology Ltd in November 2021.
Chief Financial Officer
Mr Johnson was appointed as Chief Financial Officer in January 2019. He joined AMS in October 2011 and was appointed Group Financial Controller in November 2012. Prior to this he gained a first class degree in Maths and Computer Science from Keele University in 1993 and qualified as a Chartered Accountant in 1996. Since moving into industry in 1996 Eddie has held a number of senior finance roles in various sectors including, more recently, Head of Commercial Finance at Norcros plc and Western European Financial Controller for Sumitomo Electrical Wiring Systems.
Senior Independent Non-Executive Director
Mr Cook was appointed as Non-Executive Director of AMS in February 2021. He is Chair of Molten plc, a FTSE 250 Company, and a non-executive director of Minoan plc and Sapience Communications Limited.
He has 18 years’ experience in investment banking focusing on global equity capital markets and M&A and corporate advisory. He was a Managing Director at UBS and joint Chief Executive of Panmure Gordon. He advised the London Stock Exchange on the creation of TechMark, the specialist segment of the Main Market focusing on innovative technology and healthcare companies. He has experience in the healthcare sector, most recently as Chairman of Sinclair Pharma plc and as Non-Executive Director of Morphogenesis Inc and Horizon Discovery plc. He has also held Board positions in a number of other companies including MDY Healthcare plc and Crawford Healthcare.
He holds a double first degree from Oxford University and is a member of the Institute of Chartered Accountants.
Douglas Le Fort
Mr Le Fort was appointed as Non-Executive Director of AMS in August 2021. He is currently an Operating Partner for Revival Healthcare Capital Partners, an investor in medical device and diagnostics businesses, as well as a Non-Executive Director at Trio Healthcare, a manufacturer of ostomy products, Clinisupplies, a UK based manufacturer of chronic care products and “The Insides” Company Ltd, a start up addressing intestinal failure based in New Zealand.
He is a seasoned veteran in the medical and life science industry, with more than 20 years of senior executive leadership. He has expertise in business strategy, including commercial business execution, operational management and M&A. Most recently, he was CEO of MedTrade Products, a woundcare products business and prior to that served in various senior executive roles at ConvaTec Group plc, including five years on the Executive Committee for the Group. At ConvaTec he was Senior Vice President for Corporate Development, and prior to that Vice President and General Manager with P&L responsibility for the global Ostomy business.
He has an MBA from Henley Management College and is a Chartered Management Accountant.
Liz Shanahan was appointed as Non-Executive Director of AMS in August 2022. She is currently a Non-Executive Director of Inspiration Healthcare Group plc and Celadon Pharmaceuticals plc (previously Summerway Capital plc), both of which are AIM-listed.
She is a life sciences entrepreneur with extensive experience advising leading global pharmaceutical and healthcare organisations on their communications. Most recently, she was a Non-Executive Director of UDG Healthcare plc, a company that was listed on the London Stock Exchange and a constituent of the FTSE 250 up until its £2.8 billion takeover in August 2021. Until 2014, she was Global Head of Healthcare & Lifesciences at the NYSE-listed management consultancy, FTI Consulting Inc., which in 2007 acquired the communications business Santé Communications, founded by Liz in 1995. Liz is a Trustee of CW , the charitable arm of Chelsea & Westminster Foundation Trust Hospital in London and a member of the organisation’s Innovations Advisory Board.
Alongside her Board appointments she is a business advisor and Executive coach.